PriceTargets.com logo

Opiant Pharmaceuticals - OPNT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 03/2/2023 09:00 PM ET
+0 (0.00%)
Get New Opiant Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPNT

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Opiant Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for OPNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Opiant Pharmaceuticals. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/23/2022Northland SecuritiesDowngradeOutperform ➝ Market Perform
11/22/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral
3/16/2022Cantor FitzgeraldReiterated RatingOverweight
12/8/2021OppenheimerInitiated CoverageOutperform$42.00
7/7/2021Northland SecuritiesInitiated CoverageBuy$42.00
5/1/2020Northland SecuritiesReiterated RatingBuy$42.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Opiant Pharmaceuticals logo
Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $20.58
Low: $20.03
High: $21.10

52 Week Range

Now: N/A

Volume

562,700 shs

Average Volume

77,920 shs

Market Capitalization

$108.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Opiant Pharmaceuticals?

The following equities research analysts have issued reports on Opiant Pharmaceuticals in the last twelve months:
View the latest analyst ratings for OPNT.

What is the current price target for Opiant Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Opiant Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Opiant Pharmaceuticals in the next year.
View the latest price targets for OPNT.

What is the current consensus analyst rating for Opiant Pharmaceuticals?

Opiant Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OPNT.

What other companies compete with Opiant Pharmaceuticals?

Other companies that are similar to Opiant Pharmaceuticals include GH Research, Alumis, Akebia Therapeutics, Cryoport and Procaps Group. Learn More about companies similar to Opiant Pharmaceuticals.

How do I contact Opiant Pharmaceuticals' investor relations team?

Opiant Pharmaceuticals' physical mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company's listed phone number is (310) 598-5410 and its investor relations email address is [email protected]. The official website for Opiant Pharmaceuticals is www.opiant.com. Learn More about contacing Opiant Pharmaceuticals investor relations.